Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Status:
Completed
Trial end date:
2017-08-23
Target enrollment:
Participant gender:
Summary
Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in
patients with salivary gland cancer. Researchers want to know if eribulin is safe and
effective in treating salivary gland cancer.